Ladies Luncheon Returns to Austin Country Club on September 14  for an “Afternoon in Palm Beach” Benefiting CureDuchenne  

Annual Event Features Dinner, Drinks, Raffles, Fall Fashion Show Preview and More 
to Raise Funds to Help Find a Cure for Duchenne Muscular Dystrophy  

AUSTIN, Texas (August 15, 2023) – CureDuchenne, a leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, announced the return of its annual Ladies Luncheon at the Austin Country Club on Thursday, September 14, 2023. The Ladies Luncheon, started by Austin residents Tim and Laura Revell and hosted by Venus Strawn and Jennifer Stevens, will once again bring some of the most influential women in Austin together to connect and raise funds for a cure for Duchenne muscular dystrophy. This year’s event invites attendees to experience an “Afternoon in Palm Beach” with fine dining, inspiring speakers, raffles, networking opportunities and a fall fashion show preview presented by Estilo.  

Tim and Laura Revell learned their two sons Timothy and Andrew were diagnosed with Duchenne, the most common and severe form of muscular dystrophy, at just two and five years old. At the time of their boys’ diagnoses, treatments and information on Duchenne was limited. The Revells began to research the rare disease and connected with CureDuchenne for resources. Tim and Laura have created several annual fundraising events to raise awareness and funds for CureDuchenne, including marathons, galas and the annual Ladies Luncheon. To date, the family has helped raise more than $6.2 million through their collective fundraising efforts. 

“We are endlessly in awe of the continued support we receive from the Austin community since we learned of Timothy and Andrew’s diagnosis and began our journey towards finding a cure,” said Laura Revell. “Our mission remains as strong as ever – to cure Duchenne for not only our two boys but the thousands of boys diagnosed with Duchenne and their families affected by this devastating diagnosis. Tim and I are proud to continue supporting CureDuchenne as they fund cutting-edge science that will lead to a cure.” 

Duchenne muscular dystrophy is a fatal genetic disease that affects roughly 1 in 5,000 male births. Individuals with Duchenne are typically diagnosed as toddlers, lose the ability to walk in their early-teens and often succumb to the disease in their mid-20s. Since CureDuchenne was founded in 2003, the organization has raised more than $50 million for research and funded 17 research projects that have advanced to human clinical trials. In addition, CureDuchenne develops impactful programs that help families living with Duchenne around the world. 

“We are eternally grateful to the Revells and the generous Austin community for their devotion to finding a cure for Duchenne,” said Debra Miller, Founder and CEO of CureDuchenne. “This year, the Duchenne community celebrated a significant milestone with the first FDA-approved gene therapy for Duchenne, but it is only available to very young boys. We must continue to fund research so that we can bring transformative treatments to ALL individuals with this devastating disease. Funds raised at the Ladies Luncheon will help us get us closer to a cure.” 

Tickets for the Ladies Luncheon are available for $175, and sponsorships are also available. Current sponsors include Diptyque Paris and i3 Event Marketing. For sponsorship information, tickets and event details, visit: ladies-luncheon.cureduchenne.org. 

About CureDuchenne   
Twenty years ago, CureDuchenne was created with one goal: to find and fund a cure for Duchenne muscular dystrophy, the leading genetic killer of young boys. Today, CureDuchenne is recognized as a global leader in research, patient care, and innovation for improving and extending the lives of those with Duchenne. CureDuchenne’s innovative venture philanthropy model has advanced transformative treatments for Duchenne muscular dystrophy, including 17 projects that advanced to human clinical trials and multiple projects to overcome the limitations of exon-skipping and gene therapy. In addition, CureDuchenne contributed early funding to the first FDA-approved Duchenne drug, pioneered the first and only Duchenne physical and occupational therapist certification program and created an innovative biobank and data registry, accelerating research toward a cure. For more information on how to help raise awareness and funds needed for research, please visit cureduchenne.org. 

###